|Daily Range||$24.02 - $24.24|
|52-Week Range||$21.68 - $27.87|
|Dividend (Yield)||$0.00 (3.2%)|
|Average Daily Volume||19,926|
|Current FY EPS||$0.58|
News & Commentary
Concerns over infection risks spurred action from an FDA advisory panel regarding the approval of the inflammatory bowel disease treatment vedolizumab.
Big Pharma falters again, while an underrated CNS specialist delivers a new, better, drug
Is there any hope left for VIVUS, Arena, and Orexigen -- three obesity treatment stocks that increasingly appear to be addressing a demand that simply isn’t there?
A long-awaited safety data on a popular class of type 2 diabetes drugs sends mixed messages to doctors and investors.
A look at Pfizer's top and bottom lines in the second quarter.
Is this meaningful or just another movement?
Affymax shares are taken to the woodshed due to a recall.